Open AccessP717: BOSUTINIB IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA: GASTROINTESTINAL, LIVER, EFFUSION AND RENAL SAFETY CHARACTERIZATION IN THE BFORE TRIAL
Author(s) -
Cortes J. E.,
Milojkovic D.,
GambacortiPasserini C.,
GarcíaGutiérrez V.,
Mauro M. J.,
Leip E.,
Purcell S.,
Viqueira A.,
Brümmendorf T. H.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845752.32594.93
Subject(s) - bosutinib , medicine , discontinuation , imatinib , adverse effect , meddra , gastroenterology , myeloid leukemia , oncology , dasatinib , pharmacovigilance